GLP-1 drugs carry risk of rare but serious eye condition – a physician studying these medicines explains the potential side effect

Live updates

1. 8m ago

   FDA Orders Eye Risk Warnings For GLP-1 Drugs

   Federal health regulators have ordered new warning labels for popular GLP-1 receptor agonist medications, citing a potential link to rare but severe eye conditions. Medications affected by the regulatory action include Ozempic, Wegovy, and Zepbound. The updated product warnings highlight a rare risk of vision loss and sudden blindness associated with the treatments. Physicians and researchers studying these medicines are explaining the mechanisms behind the potential side effects as patients and providers evaluate the updated safety information.

   Why it matters

   GLP-1 receptor agonists are widely used for type 2 diabetes management and chronic weight management. The regulatory mandate addresses emerging safety data concerning ocular complications. Drug manufacturers must now update their labeling to ensure patients are informed of these severe vision risks.

   What is confirmed

   • The US Food and Drug Administration ordered new eye risk warnings for popular GLP-1 drugs including Ozempic, Wegovy, and Zepbound.
   • The new warning labels highlight a risk of a rare but serious eye condition linked to sudden and permanent vision loss.

   What to watch next

   • Additional guidance from the FDA or drug manufacturers regarding specific screening recommendations for patients taking GLP-1 medications.
   • Clinical responses or statements from the makers of Ozempic, Wegovy, and Zepbound concerning the updated warning labels.
   Sources used for this update (7)

   1. CNN — US FDA orders new eye risk warnings for Ozempic, Zepbound
   2. NBC News — FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness
   3. The Washington Post — FDA tells GLP-1 makers to warn of potential vision loss side effect
   4. CNBC — FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound
   5. Fox Business — FDA orders new warning labels on Ozempic, Wegovy over rare risk of permanent vision loss
   6. The Conversation — GLP-1 drugs carry risk of rare but serious eye condition – a physician studying these medicines explains the potential side effect
   7. WBAL-TV — FDA adds warning about rare vision loss to popular GLP-1s
   confidence 100%